Panacea Hopes Bionpharma Deal Can Aid Recovery
Executive Summary
India’s Panacea Biotec is hoping an alliance with New Jersey-based pharmaceutical startup Bionpharma Inc to make seven complex generic drugs for the US with a potential market of over $800m will help its financial recovery.
You may also be interested in...
Rescue Plan For Debt-Laden Panacea Sees Shares Soar
Distressed asset fund India Resurgence Fund, run by Bain Capital and the Ajay Piramal group, has announced a $144m bailout for financially ailing Panacea Biotec.
Debt-Laden Panacea's Shares Soar As $144m Rescue Agreed
A distressed asset fund run by Bain Capital Credit and Piramal Enterprises agrees a $144m bailout for financially ailing Indian vaccines specialist Panacea Biotec.
Ukraine Nod Paves Way For Panacea Sales To 49 Other Nations
Panacea Biotec has received another piece of good news as it strives to return to profit – this time from Ukraine which has awarded a GMP certificate to the Indian drug firm to supply 22 medicinal products to the country. It also opens up 49 other nations for the firm’s products.